IDT Biologika specializes in the contract development and manufacturing of Viral Vaccines, Gene and Immunotherapeutics as well as sterile liquids and lyophilized Biologics. We help biopharmaceutical and biotech companies as well as the US government as part of research consortia with the challenging and complex process of translating viral vaccines and biopharmaceuticals from the research lab through clinical development to large-scale commercial manufacturing inculding drug substance production, fill & finish, packaging and analytics. IDT Biologika provides fully integrated services for GMP compliant end-to-end services in BSL2 facilites meeting EMA, FDA and ANVISA standards.
We strive for strong, trusting and enduring customer partnerships. Our almost 100 year tradition in manufacturing vaccines and biopharmaceuticals motivates and obligates us to advance our clients’ products to prevent and treat diseases that impact the health of people worldwide.
IDT Biologika expands portfolio of viral vaccines and biologics more info
IDT Biologika Awarded new Task Order in the Scope of 10-Year NIH Contract to Manufacture Vaccines and Biologics for Infectious Diseases more info
New building for vaccine production enables even more flexible reaction to customer demands more info
Ceva completes acquisition of IDT veterinary business assets, moving closer to its 2020 objective of 50:50 bio-pharma split more info
Divestment of animal health business unit enables focus on global growth market more info
We are making every effort to protect our employees and to ensure the manufacturing of our clients‘ vital #vaccines… https://t.co/z3O91MQYIs more info
IDT is recognized as a winner of three CMO Leadership Awards across the categories capabilities, compatibility and… https://t.co/HSFMd87yBM more info
We are proud to be awarded a silver medal for #sustainability management once again! Following the silver medal in… https://t.co/oWTvlliMtW more info
.@VWGroup and IDT Biologika celebrated the first e-crafter in Saxony-Anhalt and are now moving into the future as p… https://t.co/J8IZSg5cDy more info
Join us at #DCATWeek2020 next month in #NYC. March 24-26, 2020, Meeting Suite 1206, Hotel New York Marriot East Sid… https://t.co/XME2wKPv0S more info
IDT Biologika expands portfolio of viral #vaccines and #biologics https://t.co/TMKuYudaND #cphifrankfurt more info
RT @MDTechCouncil: Congratulations to #MTCMember: @idtbiologika Awarded New Task Order in the Scope of 10-Year NIH Contract to Manufacture… more info
"This major order from the NIAID is another important step in implementing our strategy," CEO Dr. Jürgen Betzing sa… https://t.co/yjdmODq2kA more info
IDT Biologika awarded new task order in the scope of 10-Year NIH contract to manufacture #vaccines and #biologics f… https://t.co/WxZNnmdJQY more info